PI3K Roche Nabs CE Mark for PIK3CA Test for Breast Cancer The PCR-based test detects mutations in the PIK3CA gene that can cause cells to grow uncontrollably, possibly leading to cancer. Mutations in FOXA1 Gene Can Affect Breast Cancer Patients' Response to Therapy A new study found that FOXA1 missense mutations were enriched in metastatic breast tumors and BostonGene Partners With Dana-Farber's Weinstock Lab on T-Cell Lymphoma Biomarker Research The company will provide proprietary algorithms for analyzing omics and imaging data to define predictors of drug response and identify new biomarkers. Double Mutations in PIK3CA Gene Increase Patient Sensitivity to Targeted Therapies, Study Finds Premium Researchers found that about 12 percent to 15 percent of breast cancer patients carry multiple mutations in the gene, 95 percent of which are double mutations. Cervical Cancer Exomes Point to Potentially Targetable HER, PIK3CA Pathway Changes Exome sequences from dozens of cervical cancer tumor or primary cell line samples revealed recurrent alterations affecting ERBB2/HER2 and PIK3CA pathways. Dec 7, 2018 Novartis Drug Shows Promise in PIK3CA Mutated Breast Cancer, Potential Utility of ctDNA Testing Premium Jun 3, 2018 ASCO Study Shows Modest Efficacy of PI3 Kinase Inhibitor in Molecularly Defined Breast Cancer Premium Dec 9, 2016 Novartis PI3K Inhibitor Effective in Breast Cancer Subset; Psych Toxicities Dampen Enthusiasm Premium Dec 15, 2014 Pan-Cancer Study Points to Gene Networks Prone to Rare Mutations in TCGA Tumors Dec 11, 2014 Phase II Study Shows ER/PR Status, Not PIK3CA Mutations, May ID Responders to PI3K Inhibitor Premium Sep 4, 2013 Promising Results in Cervical Cancer Subtype Study Fuel PI3K Inhibitor Trial at Dana Farber Premium Jul 15, 2010 Roche Licenses PI3K Biomarker from Qiagen to Create PCR-Based Dx Assays for Rx Development Premium Jul 14, 2010 Roche's Co-Exclusive License for PI3K Marker Will Aid in Personalization of Genentech Drugs Premium Breaking News FDA Revises SARS-CoV-2 Test Emergency Use Authorization Requirements to Account for Variants Geisinger Wins $5M NIH Grant to Develop Point-of-Care Genetic Diagnostic Tool Second Genome, Virginia Commonwealth University Partner on NASH Biomarker Discovery LGC Receives CE Mark for AccuPlex SARS-CoV-2, Flu A/B, RSV Reference Material Kit Esophageal Cancer Testing Firm Lucid Diagnostics Files For IPO Twist Bioscience, DeepCDR Collaborate on Antibody Library Design The Scan Booster for At-Risk The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk. Preprints OK to Mention Again Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications. Hundreds of Millions More to Share The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post. Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.